The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The largest prospective warfarin-treated cohort supports genetic forecasting
Open accessAbstract
Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other genes has not been fully elucidated. We genotyped 183 polymorphisms in 29 candidate genes in 1496 Swedish patients starting warfarin treatment, and tested for association with response. CYP2C9*2 and *3 explained 12% (P = 6.63 × 10−34) of the variation in warfarin dose, while a single VKORC1 SNP explained 30% (P = 9.82 × 10−100). No SNP outside the CYP2C gene cluster and VKORC1 regions was significantly associated with dose after correction for multiple testing. During initiation of therapy, homozygosity for CYP2C9 and VKORC1 variant alleles increased the risk of over-anticoagulation, hazard ratios 21.84 (95% CI 9.46; 50.42) and 4.56 (95% CI 2.85; 7.30), respectively. One of 8 patients with CYP2C9*3/*3 (12.5%) experienced severe bleeding during the first month compared with 0.27% of other patients (P = .066). A multiple regression model using the predictors CYP2C9, VKORC1, age, sex, and druginteractions explained 59% of the variance in warfarin dose, and 53% in an independent sample of 181 Swedish individuals. In conclusion, CYP2C9 and VKORC1 significantly influenced warfarin dose and predicted individuals predisposed to unstable anticoagulation. Our results strongly support that initiation of warfarin guided by pharmacogenetics would improve clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
The Structure of Haplotype Blocks in the Human Genome
Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., et al. (2002) · Science · doi:10.1126/science.1069424 · Cited by 5,863
Nyholt, D. R. (2004) · The American Journal of Human Genetics · doi:10.1086/383251 · Cited by 1,699
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Linkage Disequilibrium in Humans: Models and Data
Pritchard, J. K., & Przeworski, M. (2001) · The American Journal of Human Genetics · doi:10.1086/321275 · Cited by 1,274
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Cell biology :a laboratory handbook.
Celis, J. E. (1994) · Cited by 1,209
Pedigree disequilibrium tests for multilocus haplotypes.
Dudbridge, F. (2003) · Genetic Epidemiology · doi:10.1002/gepi.10252 · Cited by 1,135
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Cited by
Johnson, J., Caudle, K., Gong, L., Whirl‐Carrillo, M., Stein, C., Scott, S., Lee, M., Gage, B., Kimmel, S., Perera, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.668 · Cited by 716
Self-citationJohnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 647
Self-citationTakeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 632
Self-citationWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M.-T. M., Chen, C.-H., Motsinger-Reif, A., Sagreiya, H., Liu, N., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255992 · Cited by 370
Self-citationCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Metadata
- Authors
- Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-01-22
- Volume
- 113
- Issue
- 4
- Pages
- 784-792
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2017538702
- Cited by
- 550
- References
- 41
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The largest prospective warfarin-treated cohort supports genetic forecasting. https://app.cochat.ai/papers/10.1182/blood-2008-04-149070
- The paper
- Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009). The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. https://doi.org/10.1182/blood-2008-04-149070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.